167 Shares in Becton, Dickinson and Company (NYSE:BDX) Bought by Arlington Trust Co LLC

Arlington Trust Co LLC purchased a new stake in Becton, Dickinson and Company (NYSE:BDX) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 167 shares of the medical instruments supplier’s stock, valued at approximately $41,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. RVW Wealth LLC bought a new stake in Becton, Dickinson and Company in the 3rd quarter valued at $52,000. Vest Financial LLC increased its holdings in Becton, Dickinson and Company by 27.5% in the 4th quarter. Vest Financial LLC now owns 103,004 shares of the medical instruments supplier’s stock valued at $25,115,000 after buying an additional 22,207 shares during the period. M. Kulyk & Associates LLC increased its holdings in Becton, Dickinson and Company by 5.1% in the 3rd quarter. M. Kulyk & Associates LLC now owns 16,640 shares of the medical instruments supplier’s stock valued at $4,302,000 after buying an additional 809 shares during the period. SG Americas Securities LLC increased its holdings in Becton, Dickinson and Company by 69.4% in the 4th quarter. SG Americas Securities LLC now owns 15,113 shares of the medical instruments supplier’s stock valued at $3,685,000 after buying an additional 6,190 shares during the period. Finally, BKM Wealth Management LLC bought a new stake in shares of Becton, Dickinson and Company in the 4th quarter worth about $1,043,000. Institutional investors own 86.97% of the company’s stock.

Wall Street Analysts Forecast Growth

BDX has been the topic of several analyst reports. Raymond James upped their target price on shares of Becton, Dickinson and Company from $269.00 to $275.00 and gave the stock an “outperform” rating in a report on Wednesday, January 3rd. Barclays upped their target price on shares of Becton, Dickinson and Company from $301.00 to $305.00 and gave the stock an “overweight” rating in a report on Monday, February 5th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, Becton, Dickinson and Company presently has an average rating of “Moderate Buy” and a consensus price target of $280.00.

Becton, Dickinson and Company Stock Performance

Becton, Dickinson and Company stock opened at $246.17 on Monday. The company has a current ratio of 1.08, a quick ratio of 0.64 and a debt-to-equity ratio of 0.56. Becton, Dickinson and Company has a 1 year low of $229.85 and a 1 year high of $287.32. The company has a market cap of $71.12 billion, a PE ratio of 58.33, a PEG ratio of 2.03 and a beta of 0.43. The company’s 50-day moving average is $240.40 and its two-hundred day moving average is $243.90.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, February 1st. The medical instruments supplier reported $2.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.39 by $0.29. Becton, Dickinson and Company had a net margin of 6.44% and a return on equity of 13.57%. The company had revenue of $4.71 billion for the quarter, compared to the consensus estimate of $4.73 billion. During the same period in the prior year, the company posted $2.98 EPS. The company’s revenue was up 2.6% compared to the same quarter last year. Equities analysts anticipate that Becton, Dickinson and Company will post 12.94 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, March 29th. Shareholders of record on Friday, March 8th were given a dividend of $0.95 per share. The ex-dividend date was Thursday, March 7th. This represents a $3.80 dividend on an annualized basis and a yield of 1.54%. Becton, Dickinson and Company’s payout ratio is presently 90.05%.

Insider Buying and Selling at Becton, Dickinson and Company

In related news, SVP Thomas J. Spoerel sold 282 shares of the stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $238.29, for a total value of $67,197.78. Following the sale, the senior vice president now directly owns 2,276 shares in the company, valued at approximately $542,348.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.31% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.